key: cord-0740880-i18eref8
authors: Zeidan, Sinéad; Maillart, Elisabeth; Louapre, Céline; Roux, Thomas; Lubetzki, Catherine; Papeix, Caroline
title: COVID-19 infection in NMO/SD patients: a French survey
date: 2020-09-12
journal: J Neurol
DOI: 10.1007/s00415-020-10112-1
sha: 2317e1bcd66f6598a4cae12cf85d6cfd50f14d4f
doc_id: 740880
cord_uid: i18eref8

nan

Demographical and clinical characteristics of the 75 NMO/SD questioned by phone are summarized in Table 1 . During the lockdown in France (03/17/2020-05/11/2020), neurologists were available at hospital and by phone/video consults. NMO/SD treatments were maintained, including in-hospital infusions. Patients mostly stopped 100% (n = 44; 58.7%) or > 50% of their outings (n = 29; 38.7%); two patients (2.7%) continued to attend their workplace. Nine patients (12.0%) reported an interaction with a symptomatic person.

Five patients (6.7% of the whole cohort) fulfilled the diagnosis of COVID-19 (Table 2) . Their last biological analysis before COVID-19 [median (Q1-Q3) delay: 45 (10-60) days] found: grade 1 lymphopenia (n = 3/5) or normal lymphocyte count (n = 1/5), and normal neutrophilic counts (n = 4/5, missing data for one patient). The two patients receiving anti-CD20 treatment had a B-lymphocyte depletion. No patient had a severe infection or neurological state worsening. One patient treated with anti-CD20 and weekly plasmapheresis was hospitalized for closed monitoring he did not require oxygenotherapy, had a normal thoracic CT scan, and plasmapheresis was resumed three weeks later.

In this systematic survey of 75 NMO/SD patients, 6.7% had a highly suspected or confirmed COVID-19, which is consistent with the estimated seroprevalence in Ilede-France [5] . This rate is slightly higher than the 3.8% prevalence reported in an Iranian study [6] , while a large survey in China described a very low risk of COVID-19: 2 confirmed COVID-19 pneumonia out of 3060 NMO/SD patients [7] . Despite ongoing immunosuppressive therapy, no severe infection was encountered in our study. It may be related to the young age and low rate of comorbidity in the infected patients. Some authors reported a favorable outcome of COVID-19 in anti-CD20-treated patients [8, 9] , possibly due to its minor impact on T-cell counts [10] . A beneficial effect on the inflammatory response to SARS-CoV2 remains to be confirmed [11] , but other immunosuppressive treatments are studied for this purpose [12] . As we observed in 2 patients, anti-CD20 treatment may prevent the development of antibodies targeting SARS-CoV2 [8] .

Our study has limitations: the sample size is small and COVID-19 tests were poorly available during the outbreak of SARS-CoV2 in France: hence, they were not performed in asymptomatic patients. However, this systematic survey of a French NMO/SD center has resulted in the detection of mild cases of COVID-19 among this immunosuppressed population, which probably would not have been reported otherwise. It highlights a similar prevalence to the local population and a benign course of COVID-19, without any case of flare-up of the neurologic disease. Consistently with a French cohort study on MS patients [13] , this survey is reassuring about the risk of severe COVID-19 in NMO/ SD-immunosuppressed patients and supports the maintenance of immunosuppressive treatments for NMO/SD during COVID-19 pandemic. Nevertheless, social distancing should still be maintained in case of another outbreak of SARS-CoV2. 

A Review of SARS-CoV-2 and the ongoing clinical trials

The clinical course of neuromyelitis optica (Devic's syndrome)

Revised diagnostic criteria for neuromyelitis optica

International consensus diagnostic criteria for neuromyelitis optica spectrum disorders

Estimating the burden of SARS-CoV-2 in France

Evaluation of COVID-19 infection in patients with Neuromyelitis optica spectrum disorder (NMOSD): a report from Iran

Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders

COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies

Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: a case series of 60 patients from Madrid

The COVID-19 pandemic and the use of MS disease-modifying therapies

COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role

Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia

Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis